Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Checkpoint Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT06117891
What this trial is testing

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Who this might be right for
Unresectable Hepatocellular Carcinoma
Bayer 300
Testing effectiveness (Phase 2)Looking for participantsNCT06019130
What this trial is testing

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal CancerNasopharyngeal Neoplasms+1 more
German Society for Pediatric Oncology and Hematology GPOH gGmbH 57
Early research (Phase 1)WithdrawnNCT05472506
What this trial is testing

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Who this might be right for
Head and Neck Squamous Cell CarcinomaHead and Neck CancerHead Cancer+3 more
Ikena Oncology
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06047015
What this trial is testing

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Who this might be right for
Liver Metastasis Colon Cancer
University of Saskatchewan 12
Early research (Phase 1)Study completedNCT03990233
What this trial is testing

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Who this might be right for
Solid Tumor, Adult
OSE Immunotherapeutics 100
Large-scale testing (Phase 3)Looking for participantsNCT05727904
What this trial is testing

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Who this might be right for
Metastatic MelanomaUnresectable MelanomaMelanoma
Iovance Biotherapeutics, Inc. 670
Testing effectiveness (Phase 2)UnknownNCT05151549
What this trial is testing

Carilizumab Combined With Concurrent Chemoradiotherapy

Who this might be right for
Cervical Cancer
Hunan Cancer Hospital 46
Early research (Phase 1)Study completedNCT04477512
What this trial is testing

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Washington University School of Medicine 18
Early research (Phase 1)Looking for participantsNCT06940440
What this trial is testing

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

Who this might be right for
Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc. 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT02484404
What this trial is testing

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Who this might be right for
Colorectal NeoplasmsBreast Neoplasms
National Cancer Institute (NCI) 268
Testing effectiveness (Phase 2)Ended earlyNCT04034225
What this trial is testing

Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Sensei Biotherapeutics, Inc. 25
Early research (Phase 1)Active Not RecruitingNCT06125197
What this trial is testing

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
TILT Biotherapeutics Ltd. 22
Testing effectiveness (Phase 2)UnknownNCT03506997
What this trial is testing

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Institute of Cancer Research, United Kingdom 100
Testing effectiveness (Phase 2)Looking for participantsNCT07381634
What this trial is testing

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Who this might be right for
Hepatocellular Carcinoma (HCC)IrAE
First Affiliated Hospital of Wenzhou Medical University 134
Testing effectiveness (Phase 2)Ended earlyNCT05572684
What this trial is testing

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsMicrosatellite Instability LowMicrosatellite Instability High+9 more
NextCure, Inc. 97
Early research (Phase 1)Looking for participantsNCT07231458
What this trial is testing

Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Who this might be right for
Advanced Solid Tumors
Abalos Therapeutics GmbH 27
Testing effectiveness (Phase 2)UnknownNCT04800978
What this trial is testing

Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy

Who this might be right for
Cervical Cancer
Samsung Medical Center 37
Early research (Phase 1)Active Not RecruitingNCT02879695
What this trial is testing

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic Leukemia+1 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07836101
What this trial is testing

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

Who this might be right for
Any Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 41
Not applicableLooking for participantsNCT06519292
What this trial is testing

Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer

Who this might be right for
Cardiovascular DiseasesArterial ThrombosisMyocardial Infarction+4 more
Hanneke W. M. van Laarhoven 214
Next Page